|
| Q-9. |
What is the breakdown by type of business? |
|
|
We are predominantly a dosage form company, with 84% of sales from prescription products. APIs account for 16% of sales.
Domestic formulations, the sale of speciality prescription brands in India, account for about 55% of sales. International markets are about 40% of sales. Of this, the US generic business at Caraco is 22%. (For the year ending March 31, 2006) |
|
|
| Q-10. |
What are the company's capex plans? |
|
|
Typically Rs. 1,000 million are invested every year in capacity expansion at the current sites. This is in addition to the Rs. 2,000 million we invest annually, at 10-12% of turnover, in R&D. |
|
|
| Q-11. |
Will the demerger change my holding in Sun Pharma? Will I have to fill in any form to get the shares of the new company? |
|
|
The demerger will not change your holding in Sun Pharma, since you would receive one share of the R&D company for one share of Sun Pharma that you hold. Since these shares would be automatically credited to your demat account, no forms have to be filled in. |
|
|
| Q-12. |
Who is the transfer agent? What can the transfer agent help me with? |
|
|
Any communication related to share transfer and share certificates, dividend and change of address to be addressed to: |
|
|
|
Intime Spectrum Registry Ltd.
C13 Pannalal Silk Mills Compound,
LBS Marg,
Bhandup (W),
Mumbai - 400 078.
Mail: sunpharma@intimespectrum.com |
|
|
|
|
|
News Articles
Contact Us
